ATE320803T1 - Verfahren zur behandlung von alzheimerschen krankheit - Google Patents
Verfahren zur behandlung von alzheimerschen krankheitInfo
- Publication number
- ATE320803T1 ATE320803T1 AT98960605T AT98960605T ATE320803T1 AT E320803 T1 ATE320803 T1 AT E320803T1 AT 98960605 T AT98960605 T AT 98960605T AT 98960605 T AT98960605 T AT 98960605T AT E320803 T1 ATE320803 T1 AT E320803T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- treating alzheimer
- lowering agent
- alzheimer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7291298P | 1998-01-28 | 1998-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE320803T1 true ATE320803T1 (de) | 2006-04-15 |
Family
ID=22110517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98960605T ATE320803T1 (de) | 1998-01-28 | 1998-12-02 | Verfahren zur behandlung von alzheimerschen krankheit |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1051161B1 (de) |
| JP (1) | JP2002501887A (de) |
| KR (2) | KR20010034417A (de) |
| AT (1) | ATE320803T1 (de) |
| AU (1) | AU762124B2 (de) |
| BR (1) | BR9814923A (de) |
| CA (1) | CA2311356C (de) |
| DE (1) | DE69833971T2 (de) |
| ES (1) | ES2257824T3 (de) |
| NZ (1) | NZ505761A (de) |
| WO (1) | WO1999038498A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| US6472421B1 (en) * | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
| NZ518822A (en) * | 1999-11-04 | 2004-12-24 | Andrx Corp | Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor |
| US20010028895A1 (en) * | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
| MXPA02010762A (es) * | 2000-06-07 | 2003-03-10 | Warner Lambert Co | Combinaciones de carboxialquileter-inhibidores acat. |
| US7439052B2 (en) | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| US7407662B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| US7407663B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| KR20070120617A (ko) | 2001-01-26 | 2007-12-24 | 쉐링 코포레이션 | 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물 |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| ES2290562T3 (es) | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
| WO2002062824A2 (en) * | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid ? precursor disorder |
| AU2002243883A1 (en) * | 2001-02-07 | 2002-08-19 | The Mclean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| US20030013699A1 (en) * | 2001-05-25 | 2003-01-16 | Davis Harry R. | Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject |
| US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20060060520A1 (en) | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| AU2002322284A1 (en) | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| BR0308871A (pt) * | 2002-04-05 | 2005-01-04 | Sankyo Co | Composição farmacêutica |
| JP2004002365A (ja) * | 2002-04-05 | 2004-01-08 | Sankyo Co Ltd | Acat阻害剤とインシュリン抵抗性改善剤とからなる医薬組成物 |
| MXPA05004810A (es) | 2002-11-06 | 2005-07-22 | Schering Corp | Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion. |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| WO2004081004A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| EP1601669B1 (de) | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| PT1641421T (pt) | 2003-07-03 | 2019-03-27 | Hdl Therapeutics Inc | Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido |
| EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| JP5145537B2 (ja) | 2004-12-22 | 2013-02-20 | ビーエイチアイ リミテッド パートナーシップ | アミロイド関連疾患を治療するための方法および組成物 |
| US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| ATE481094T1 (de) | 2005-12-22 | 2010-10-15 | Kiacta Sarl | Behandlung von diabetischer nephropathie |
| CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
| ES2967330T3 (es) | 2006-10-12 | 2024-04-29 | Bellus Health Inc | Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico |
| AU2008271178A1 (en) | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as CB1 antagonists |
| US20140370011A1 (en) * | 2009-06-04 | 2014-12-18 | Dara Biosciences, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives |
| US20180200230A1 (en) * | 2009-06-04 | 2018-07-19 | Dara Biosciences, Inc. | Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier |
| DK2844256T3 (da) | 2012-05-02 | 2023-03-27 | Univ Georgetown | Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer |
| JP6483711B2 (ja) * | 2013-09-18 | 2019-03-13 | ジョージタウン・ユニバーシティGeorgetown University | フェノフィブラート及びその類似体を用いた神経変性疾患の治療 |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| US20170354666A1 (en) | 2014-11-19 | 2017-12-14 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| ES3020757T3 (en) | 2017-11-22 | 2025-05-23 | Hdl Therapeutics Inc | Methods for priming fluid circuits of a plasma processing system |
| EP3731814A4 (de) | 2017-12-28 | 2021-09-29 | HDL Therapeutics, Inc. | Verfahren zur konservierung und verabreichung von aus menschlichem plasma extrahiertem prä-beta-lipoprotein hoher dichte |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248785A (en) * | 1990-02-12 | 1993-09-28 | Virginia Commonwealth University | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| WO1995006470A1 (en) * | 1993-08-30 | 1995-03-09 | Merck & Co., Inc. | Prevention and treatment of alzheimer's disease |
| JPH08143454A (ja) * | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
| US6537987B1 (en) * | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
| US5965553A (en) * | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
| WO1998016216A1 (en) * | 1996-10-11 | 1998-04-23 | Scotia Holdings Plc | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
| EP1006794B1 (de) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
| DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
-
1998
- 1998-12-02 AT AT98960605T patent/ATE320803T1/de not_active IP Right Cessation
- 1998-12-02 EP EP98960605A patent/EP1051161B1/de not_active Expired - Lifetime
- 1998-12-02 CA CA002311356A patent/CA2311356C/en not_active Expired - Fee Related
- 1998-12-02 KR KR1020007008187A patent/KR20010034417A/ko not_active Ceased
- 1998-12-02 WO PCT/US1998/025495 patent/WO1999038498A1/en not_active Ceased
- 1998-12-02 DE DE69833971T patent/DE69833971T2/de not_active Expired - Fee Related
- 1998-12-02 KR KR1020067000221A patent/KR100592842B1/ko not_active Expired - Fee Related
- 1998-12-02 JP JP2000529231A patent/JP2002501887A/ja active Pending
- 1998-12-02 AU AU16165/99A patent/AU762124B2/en not_active Ceased
- 1998-12-02 BR BR9814923-7A patent/BR9814923A/pt not_active Application Discontinuation
- 1998-12-02 NZ NZ505761A patent/NZ505761A/en unknown
- 1998-12-02 ES ES98960605T patent/ES2257824T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU1616599A (en) | 1999-08-16 |
| DE69833971T2 (de) | 2006-11-02 |
| WO1999038498A1 (en) | 1999-08-05 |
| ES2257824T3 (es) | 2006-08-01 |
| DE69833971D1 (de) | 2006-05-11 |
| JP2002501887A (ja) | 2002-01-22 |
| AU762124B2 (en) | 2003-06-19 |
| KR20060009409A (ko) | 2006-01-31 |
| CA2311356C (en) | 2004-07-13 |
| BR9814923A (pt) | 2000-10-17 |
| EP1051161B1 (de) | 2006-03-22 |
| KR20010034417A (ko) | 2001-04-25 |
| CA2311356A1 (en) | 1999-08-05 |
| EP1051161A1 (de) | 2000-11-15 |
| KR100592842B1 (ko) | 2006-06-26 |
| NZ505761A (en) | 2003-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
| DE69521700D1 (de) | Mittel und methoden zur behandlung von plaque-krankheiten | |
| ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
| DE60239612D1 (de) | Monodisperse mischungen und verfahren zur behandlung von diabetes | |
| ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| ATE342728T1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| WO2001058476A3 (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
| FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
| ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| EP0932613A4 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
| DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
| WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
| ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| ATE371453T1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |